Osteoarthritis (OA) and intervertebral disc degeneration (IVDD) as major cause of chronic low back pain represent the most common degenerative joint pathologies and are leading causes of pain and disability in adults. Articular cartilage (AC) and intervertebral discs are cartilaginous tissues with a similar biochemical composition and pathophysiological aspects of degeneration. Although treatments directed at reversing these conditions are yet to be developed, many promising disease-modifying drug candidates are currently under investigation. Given the localized nature of these chronic diseases, drug delivery systems have the potential to enhance therapeutic outcomes by providing controlled and targeted release of bioactives, minimizing the number of injections needed and increasing drug concentration in the affected areas. This review provides a comprehensive overview of the currently most promising disease-modifying drugs as well as potential drug delivery systems for OA and IVDD therapy.
To date no disease-modifying drugs for osteoarthritis (OA) are available, with treatment limited to the use of pain killers and prosthetic replacement. The ADAMTS (A Disintegrin and Metallo Proteinase with Thrombospondin Motifs) enzyme family is thought to be instrumental in the loss of proteoglycans during cartilage degeneration in OA, and their inhibition was shown to reverse osteoarthritic cartilage degeneration. Locked Nucleic Acid (LNA)-modified antisense oligonucleotides (gapmers) released from biomaterial scaffolds for specific and prolonged ADAMTS inhibition in co-delivered and resident chondrocytes, is an attractive therapeutic strategy. Here, a gapmer sequence identified from a gapmer screen showed 90% ADAMTS5 silencing in a monolayer culture of human OA chondrocytes. Incorporation of the gapmer in a fibrin-hyaluronic acid hydrogel exhibited a sustained release profile up to 14 days. Gapmers loaded in hydrogels were able to transfect both co-embedded chondrocytes and chondrocytes in a neighboring gapmer-free hydrogel, as demonstrated by flow cytometry and confocal microscopy. Efficient knockdown of ADAMTS5 was shown up to 14 days in both cell populations, i.e. the gapmer-loaded and gapmer-free hydrogel. This work demonstrates the use applicability of a hydrogel as a platform for combined local delivery of chondrocytes and an ADAMTS-targeting gapmer for catabolic gene modulation in OA.
Intervertebral disc (IVD) degeneration is suggested as a major cause of chronic low back pain (LBP). Intradiscal delivery of growth factors has been proposed as a promising strategy for IVD repair and regeneration. Previously, BMP-4 was shown to be more potent in promoting extracellular matrix (ECM) production than other BMPs and TGF-β in human nucleus pulposus (NP) cells, suggesting its applicability for disc regeneration. The effects of BMP-4 on ECM deposition and cell proliferation were assessed in sheep NP and annulus fibrosus (AF) cells in a pellet culture model. Further, a nuclectomy induced sheep lumbar IVD degeneration model was used to evaluate the safety and effects of intradiscal BMP-4 injection on IVD regeneration. Outcomes were assessed by magnetic resonance imaging, micro-computed tomography, histological and biochemical measurements. In vitro, BMP-4 significantly increased the production of proteoglycan and deposition of collagen type II and proliferation of NP and AF cells. Collagen type I deposition was not affected in NP cells, while in AF cells it was high at low BMP-4 concentrations, and decreased with increasing concentration of BMP-4. Intradiscal injection of BMP-4 induced extradiscal new bone formation and Schmorl's node-like changes in vivo. No regeneration in the NP nor AF was observed. Our study demonstrated that although BMP-4 showed promising regenerative effects in vitro, similar effects were not observed in a large IVD degeneration animal model. The contradictory results of using BMP-4 on IVD regeneration between in vitro and in vivo demonstrate that direct BMP-4 injection for disc degeneration-associated human chronic low back pain should not be undertaken. In addition, our results may also shed light on the mechanisms behind pathological endplate changes in human patients as a possible target for therapy.
Background/Objective: The development of regenerative therapies for osteoarthritis and intervertebral disc degeneration requires non-destructive methods to spatiotemporally monitor extracellular matrix (ECM) synthesis. This study aimed to establish and validate bioorthogonal click chemistry for specific, quantitative, and spatially resolved tracking of newly synthesized proteoglycans in cartilaginous tissues. Methods: Bovine articular cartilage explants, human nucleus pulposus tissue, and human and chondrocyte cultures were metabolically labeled using azide-modified N-acetylgalactosamine (Ac4GalNAz) incorporation with copper-catalyzed and copper-free click chemistry. GAG-specific incorporation was verified by enzymatic digestion with chondroitinase ABC(ChABC) and hyaluronidase(HAse). Sequential labeling with spectrally distinct fluorophores enabled temporal tracking of matrix deposition. Volumetric quantification was performed using ImageJ on confocal microscopy Z-stacks. Near-infrared (NIR) dyes were employed for in vitro and subcutaneous imaging, with photoacoustic imaging used to enhance spatial resolution. Results: Ac4GalNAz demonstrated negligible cytotoxicity at 50 μM in cartilage explants. In tissue explants, metabolic labeling showed high specificity for chondroitin sulfate(CS)-containing proteoglycans, confirmed by ChABC digestion. In contrast, 2D chondrocyte cultures showed ChABC-resistant labeling, suggesting incorporation into membrane-associated glycoproteins. Sequential copper-free labeling distinguished temporally distinct matrix synthesis within the same sample. NIR-labeled explants were detectable both in vitro and following subcutaneous implantation, with only a moderate loss of signal intensity. Photoacoustic imaging provided superior spatial resolution, enabling clear visualization of implant structure. Conclusions: Bioorthogonal metabolic labeling enables non-destructive, spatially resolved, and quantitative monitoring of proteoglycan synthesis in cartilaginous tissues. Labeling specificity is tissue-context dependent, requiring enzymatic validation for each model system. Integration with NIR fluorescence and photoacoustic imaging provides a foundation for future in vivo applications.